About tbcr
Manuscript Submission
AME Editing Service
Reprint & Permission
Advertising
Contact us
-
General editorial enquiries:
Email: tbcr@amegroups.com -
Copyright related enquiries:
Email: permissions@amegroups.com -
Commercial sales contact (reprints, advertising, etc.):
Email: sales@amegroups.com
Case Report
Translational Breast Cancer Research
2024;
5:
17
(30 April 2024)
Editorial Commentary
Translational Breast Cancer Research
2024;
5:
16
(30 April 2024)
Editorial Commentary
Translational Breast Cancer Research
2024;
5:
15
(30 April 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
14
(30 April 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
13
(30 April 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
12
(30 April 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
11
(30 April 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
10
(30 April 2024)
Expert Consensus
Translational Breast Cancer Research
2024;
5:
9
(30 April 2024)
Case Report
Translational Breast Cancer Research
2024;
5:
8
(31 January 2024)
Case Report
Translational Breast Cancer Research
2024;
5:
7
(31 January 2024)
Brief Report
Translational Breast Cancer Research
2024;
5:
6
(31 January 2024)
Editorial Commentary
Translational Breast Cancer Research
2024;
5:
5
(31 January 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
4
(31 January 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
3
(31 January 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
2
(31 January 2024)
Review Article
Translational Breast Cancer Research
2024;
5:
1
(31 January 2024)
Case Report
Translational Breast Cancer Research
2023;
4:
33
(31 October 2023)
Editorial
Translational Breast Cancer Research
2023;
4:
32
(31 October 2023)
Editorial
Translational Breast Cancer Research
2023;
4:
31
(31 October 2023)
Editorial Commentary